<SEC-DOCUMENT>0001534120-26-000032.txt : 20260513
<SEC-HEADER>0001534120-26-000032.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513070044
ACCESSION NUMBER:		0001534120-26-000032
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avalo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001534120
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450705648
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37590
		FILM NUMBER:		26970870

	BUSINESS ADDRESS:	
		STREET 1:		1500 LIBERTY RIDGE DRIVE
		STREET 2:		SUITE 321
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		410-522-8707

	MAIL ADDRESS:	
		STREET 1:		1500 LIBERTY RIDGE DRIVE
		STREET 2:		SUITE 321
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerecor Inc.
		DATE OF NAME CHANGE:	20111102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>avtx-20260513.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d884e-17de-7c58-b5b5-b6da95e6fa21,g:c64acb00-4d7d-4d2e-ae32-34da6feee8cd,d:65e3e96872534e309eef5af851eee875-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>avtx-20260513</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001534120</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="avtx-20260513.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-13</xbrli:startDate><xbrli:endDate>2026-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65e3e96872534e309eef5af851eee875_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="padding-left:216pt;padding-right:216pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 13, 2026</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">AVALO THERAPEUTICS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:370.50pt"><tr><td style="width:1.0pt"/><td style="width:96.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:148.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37590</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">45-0705648</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1500 Liberty Ridge Drive, Suite 321</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Wayne</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">19087</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">410</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">522-8707</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="padding-left:60.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%"> &#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:60.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:60.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:60.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">AVTX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div style="padding-left:360pt;text-align:right;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Growth Company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="i65e3e96872534e309eef5af851eee875_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-right:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:115%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:112%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Exhibits:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-9911q2026earningsrelease.htm">Press release, dated Ma</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-9911q2026earningsrelease.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-9911q2026earningsrelease.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-9911q2026earningsrelease.htm">13</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-9911q2026earningsrelease.htm">, 2026.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:138%;text-decoration:underline">SIGNATURE</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:138%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:23.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.598%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">AVALO THERAPEUTICS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Date: May 13, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Christopher Sullivan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Christopher Sullivan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-9911q2026earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i5f75b3132eb141409b97fb9887338401_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font><br></font></div><div><img alt="avalo-logoxblk1a.jpg" src="avalo-logoxblk1a.jpg" style="height:109px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Completed public offering of equity securities for gross proceeds of $431.3 million  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WAYNE, PA, May 13, 2026 &#8212; Avalo Therapeutics, Inc. (Nasdaq&#58; AVTX) (&#8220;Avalo&#8221;), a clinical stage biotechnology company fully dedicated to developing IL-1&#946;-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8220;The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">clinical response across both HiSCR75 and HiSCR50 endpoints, mark the beginning of a transformative period for Avalo,&#8221; said Garry Neil, MD, Chief Executive Officer of Avalo. &#8220;With our recently secured financing, Avalo is well-positioned to advance abdakibart into a registrational phase 3 program. Our focus remains on delivering this innovative mechanism of action via a patient-friendly potential monthly dosing regimen to provide a much-needed new treatment option for those living with HS.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Recent Corporate Highlights&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">On May 5, 2026, Avalo reported positive topline Phase 2 LOTUS results for abdakibart in adults with moderate to severe HS. The trial successfully met its primary endpoint at both doses studied (p&#61;0.018 150mg, p&#61;0.015 300mg and p&#61;0.004, combined), demonstrating a 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16, respectively (42.5% combined&#59; placebo rate 25.6%). These results represented the highest absolute improvement in HiSCR75 and HiSCR50 reported in similarly sized (or larger) HS trials at each individual dose and on a combined dose basis. Abdakibart also demonstrated statistically significant benefit across the key secondary endpoints, including HiSCR50, change in IHS4, and change in draining tunnel count.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.8pt">On </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">May 7, 2026</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">, Avalo completed an underwritten public offering of its common stock and pre-funded warrants to purchase shares of common stock for gross proceeds of $431.3 million. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">On April 26, 2026, Avalo entered into a Milestone Buyout Option and Amendment Agreement related to its March 2024 acquisition of AlmataBio, Inc. Under the agreement, Avalo paid the former AlmataBio securityholders $2.25 million for an option, exercisable within 90 days of the effective date, to pay $5.125 million in cash or shares of Avalo common stock (or a combination) in lieu of the previously disclosed $15 million contingent milestone payment due upon dosing the first patient in a Phase 3 trial of abdakibart.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2026 Financial Update&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:13.8pt">Cash, cash equivalents and short-term investments </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">were $82.0 million as of March 31, 2026. Net cash used in operating activities was $17.7 million for the three months ended March 31, 2026. Subsequent to March 31, 2026, the Company completed an underwritten public offering of its common </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">stock and pre-funded warrants for net proceeds of approximately $405.0 million. Our current cash, cash equivalents, and short-term investments are expected to fund operations into 2029. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Research and development expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $14.0 million for the three months ended March 31, 2026, an increase of $4.9 million from the prior year, driven by costs related to and supporting the Phase 2 LOTUS trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">General and administrative expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">were $6.9 million for the three months ended March 31, 2026, an increase of $1.3 million from the prior year, primarily driven by headcount additions and stock-based compensation expense.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Net loss </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">was $19.6 million for the three months ended March 31, 2026, as compared to net loss of $13.1 million for the three months ended March 31, 2025. The difference was driven by a $6.2&#160;million increase in operating expenses due to the $4.9 million increase in research and development expenses, as discussed above, and $1.3 million increase in general and administrative expenses, as discussed above. Basic and diluted net loss per share was $0.98 and $1.25 for the three months ended March 31, 2026 and 2025, based on 20,106,925 and 10,514,901 weighted average common shares outstanding, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f75b3132eb141409b97fb9887338401_4"></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(In thousands, except share and per share data)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:70.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,988&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,005&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,478&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,913&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,825&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,286&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,885&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,458&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, mezzanine equity and stockholders&#8217; equity </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,599&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,940&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability, non-current</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,565&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,409&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Preferred Stock&#8212;$0.001 par value&#59; 1 share of Series D Preferred Stock authorized at March&#160;31, 2026 and December&#160;31, 2025&#59; 1 share of Series D Preferred Stock issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Preferred Stock&#8212;$0.001 par value&#59; 1 share of Series E Preferred Stock authorized at March&#160;31, 2026 and December&#160;31, 2025&#59; 1 share of Series E Preferred Stock issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;$0.001 par value&#59; 200,000,000 shares authorized at March&#160;31, 2026 and December&#160;31, 2025&#59; 24,637,807 and 18,512,757 shares issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025, respectively</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Preferred Stock&#8212;$0.001 par value&#59; 34,326 shares of Series C Preferred Stock authorized at March&#160;31, 2026 and December&#160;31, 2025&#59; 13,036 and 18,792 shares of Series C Preferred Stock issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025, respectively</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,453&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,485&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(468,152)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448,522)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,320&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,049&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, mezzanine equity and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,885&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,458&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated balance sheets as of March 31, 2026 and December 31, 2025 have been derived from the reviewed and audited financial statements, respectively, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.</font></div><div id="i5f75b3132eb141409b97fb9887338401_7"></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Consolidated Statements of Operations</font></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(In thousands, except per share data)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:70.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,854&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,901&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,669&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,901)</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,669)</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,618)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,141)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,630)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,149)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock, basic and diluted </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.25)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,106,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,901&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated statements of operations for the three months ended March 31, 2026 and 2025 have been derived from the reviewed financial statements, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.</font></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div id="i5f75b3132eb141409b97fb9887338401_10"></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Avalo Therapeutics </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1&#946;-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1&#946; monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). We&#8217;re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit  </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.avalotx.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f75b3132eb141409b97fb9887338401_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Abdakibart </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Abdakibart is a humanized monoclonal antibody (IgG4) that binds to interleukin-1&#946; (IL-1&#946;) with high affinity and neutralizes its activity. IL-1&#946; is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.1 It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-&#945;, and IL-17. Dysregulated IL-1&#946; signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1&#946; inhibition has proven effective in multiple immune-mediated inflammatory diseases.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">1-3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About the LOTUS Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The LOTUS trial was a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two dose regimens to evaluate the efficacy, safety and tolerability of abdakibart in approximately 250 adults with moderate to severe hidradenitis suppurativa. Subjects were randomized (1&#58;1&#58;1) to receive either one of two dosing regimens of abdakibart or placebo during a 16-week treatment phase. The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16. Secondary objectives include but are not limited to&#58; the proportion of patients achieving HiSCR50 and HiSCR90 as well as change from baseline in&#58; International HS Severity Score System (IHS4), draining tunnel count, abscess and inflammatory nodule (AN) count, and patients achieving at least a 30% reduction on a numerical rating scale in Patient's Global Assessment of Skin Pain (PGA Skin Pain). For additional information this trial (</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NCT06603077</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">), please visit </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.clinicaltrials.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> or </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.lotustrial.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Hidradenitis Suppurativa</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Hidradenitis suppurativa (HS) is a chronic, progressive, often debilitating inflammatory skin disease that causes painful nodules, abscesses, and tunnels to form under the skin.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:107%;position:relative;top:-3.85pt;vertical-align:baseline">4-6,8 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Areas commonly affected by HS include the nape of the neck, breasts, chest, armpits, abdomen, buttocks and anus, groin and genitals, and inner thighs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:107%;position:relative;top:-3.85pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> If not adequately and promptly treated, the chronic inflammation characteristic of HS may progress to tissue destruction and permanent scarring.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:107%;position:relative;top:-3.85pt;vertical-align:baseline">4-6,9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> HS typically first presents in late adolescence or early adulthood and is estimated to affect 0.7&#8211;1.2% of the U.S. population, though some sources suggest the prevalence may be as high as 2&#8211;4%.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:107%;position:relative;top:-3.85pt;vertical-align:baseline">10,11,12</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">References&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Dinarello CA. Immunol Rev. 2018&#59;281(1)&#58;8-27. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Kany S et al. Int J Mol Sci. 2019&#59;20(23)&#58;6008. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Kimball AB et al. Presented at&#58; American Academy of Dermatology&#59; March 8-12, 2024&#59; San Diego, CA. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Diaz MJ, et al. Curr Iss Mol Bio. 2023&#59;45&#58;4400-4415. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Agnese ER, et al. Cureus. 2023&#59;15(11)&#58;e49390. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">de Oliveira ASLE, et al. Biomolecules. 2022&#59;12(10)&#58;1371. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Ingram JR, et al. J Eur Acad Dermatol Venereol. 2022&#59;36(9)&#58;1597-160. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Sabat R, et al. The Lancet. 2025&#59;405(10476)&#58;P420-438. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Jemec GB. Clinicalpractice. Hidradenitis suppurativa. N Engl J Med. 2012&#59;366(2)&#58;158&#8211;164. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017&#59;153(8)&#58;760&#8211;764. doi&#58;10.1001&#47;jamadermatol.2017.0201. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Ingram, John R.British Journal of Dermatology. doi&#58;10.1111&#47;bjd.19435. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Nguyen TV, et al. J Eur Acad Dermatol Venereol. 2021&#59;35(1)&#58;50-61.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div id="i5f75b3132eb141409b97fb9887338401_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond our control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to our plans, objectives, projections, expectations and intentions and other statements identified by words such as &#8220;projects,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;predicts,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; or similar expressions (including their use in the negative), or by discussions of future matters such as&#58; therapeutic </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">potential, clinical benefits and safety profiles of abdakibart (AVTX-009)&#59; plans to advance abdakibart into a registrational phase 3 program&#59; expectations regarding timing, success and data announcements of ongoing preclinical studies and clinical trials&#59; drug development costs, reliance on investigators and enrollment of patients in clinical trials&#59; and our plans to develop and commercialize our current and any future product candidates and the implementation of our business model and strategic plans for our business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any forward-looking statements are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements including, without limitation, risks associated with&#58; the timing and anticipated results of our current and future preclinical studies and clinical trials, supply chain, strategy and future operations&#59; the delay of any current and future preclinical studies or clinical trials or the development of our product candidates&#59; the risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for abdakibart&#59; the risk that cross-trial comparisons may not be reliable as no head-to-head trials of abdakibart have been conducted&#59; the timing and outcome of any interactions with regulatory authorities&#59; obtaining, maintaining and protecting our intellectual property&#59; the availability of funding sufficient for our operating expenses and capital expenditure requirements, reliance on key personnel&#59; regulatory risks&#59; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East&#59; and those other risks detailed in our filings with the Securities and Exchange Commission, available at www.sec.gov. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. In addition, any forward-looking statements represent our view only as of today and should not be relied upon as representing its views as of any subsequent date. You should not rely upon forward-looking statements as predictions of future events and actual results or events could differ materially from the plans, intentions and expectations disclosed herein. Except as required by applicable law, we expressly disclaim any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f75b3132eb141409b97fb9887338401_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:130%">For media and investor inquiries</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Christopher Sullivan, CFO </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Avalo Therapeutics, Inc. </font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ir&#64;avalotx.com</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">410-803-6793</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Meru Advisors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lauren Glaser</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">lglaser&#64;meruadvisors.com</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>avtx-20260513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d884e-17de-7c58-b5b5-b6da95e6fa21,g:c64acb00-4d7d-4d2e-ae32-34da6feee8cd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:avtx="http://www.avalotherapeutics.com/20260513" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.avalotherapeutics.com/20260513">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20260513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20260513_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20260513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.avalotherapeutics.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>avtx-20260513_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d884e-17de-7c58-b5b5-b6da95e6fa21,g:c64acb00-4d7d-4d2e-ae32-34da6feee8cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CoverPageDocument" xlink:type="simple" xlink:href="avtx-20260513.xsd#CoverPageDocument"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_019d884e-17de-77f8-8dce-cd1ba51951dc_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:to="loc_dei_AddressTypeDomain_019d884e-17de-77f8-8dce-cd1ba51951dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_019d884e-17de-70b9-98fe-1386bbf65561" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:to="loc_dei_AddressTypeDomain_019d884e-17de-70b9-98fe-1386bbf65561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019d884e-17de-728e-b38a-b6d19555f0ed" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressStateOrProvince_019d884e-17de-728e-b38a-b6d19555f0ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019d884e-17de-7dc9-ab2b-16c9b19ab947" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressCityOrTown_019d884e-17de-7dc9-ab2b-16c9b19ab947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019d884e-17de-794d-9b8b-0f7436a93513" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressPostalZipCode_019d884e-17de-794d-9b8b-0f7436a93513" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019d884e-17de-7508-b6b0-5b3064f8fd27" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_DocumentType_019d884e-17de-7508-b6b0-5b3064f8fd27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019d884e-17de-7a7b-b251-4db13e33cee8" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_DocumentPeriodEndDate_019d884e-17de-7a7b-b251-4db13e33cee8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019d884e-17de-782e-a191-fedfa09e3751" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityRegistrantName_019d884e-17de-782e-a191-fedfa09e3751" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019d884e-17de-7118-a8d1-f94e31e65ffe" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019d884e-17de-7118-a8d1-f94e31e65ffe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019d884e-17de-74ad-9764-98a8bd5febd5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityFileNumber_019d884e-17de-74ad-9764-98a8bd5febd5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019d884e-17de-7dda-b838-6f9707719d02" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityTaxIdentificationNumber_019d884e-17de-7dda-b838-6f9707719d02" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019d884e-17de-7f70-b7a9-94e6e855721a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressAddressLine1_019d884e-17de-7f70-b7a9-94e6e855721a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019d884e-17de-7910-a5ce-ad4ec8ace0e9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019d884e-17de-71e9-a602-044821929db1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019d884e-17de-7651-9f74-2f69d3054d1c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019d884e-17de-75a2-bc3f-013016620f98" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_CityAreaCode_019d884e-17de-75a2-bc3f-013016620f98" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019d884e-17de-7079-a2cc-ec0ddcc5f6a5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_LocalPhoneNumber_019d884e-17de-7079-a2cc-ec0ddcc5f6a5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019d884e-17de-7582-aa19-9b75b349f0c5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_WrittenCommunications_019d884e-17de-7582-aa19-9b75b349f0c5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019d884e-17de-7710-99ac-cce8976c1368" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_SolicitingMaterial_019d884e-17de-7710-99ac-cce8976c1368" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019d884e-17de-7523-8707-9678109b27db" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_PreCommencementTenderOffer_019d884e-17de-7523-8707-9678109b27db" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019d884e-17de-7f1c-813d-5b032efad680" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019d884e-17de-7f1c-813d-5b032efad680" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019d884e-17de-715b-9ed2-cef93879312b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_Security12bTitle_019d884e-17de-715b-9ed2-cef93879312b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019d884e-17de-7d7d-8aa5-a4245e73f282" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_TradingSymbol_019d884e-17de-7d7d-8aa5-a4245e73f282" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019d884e-17de-7590-b18d-d2984fdfeae2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityEmergingGrowthCompany_019d884e-17de-7590-b18d-d2984fdfeae2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019d884e-17de-7d56-a9a4-0e0643f6ff4e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityCentralIndexKey_019d884e-17de-7d56-a9a4-0e0643f6ff4e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019d884e-17de-7f45-b12b-602b3af53034" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_AmendmentFlag_019d884e-17de-7f45-b12b-602b3af53034" xlink:type="arc" order="23"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>avtx-20260513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d884e-17de-7c58-b5b5-b6da95e6fa21,g:c64acb00-4d7d-4d2e-ae32-34da6feee8cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019d884e-17de-73f9-8a08-62a6c038791b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019d884e-17de-7f2d-80b2-f32950aed281_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019d884e-17de-7354-abbf-ca2086ae31ab_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019d884e-17de-7e31-a666-4a2ea7255c25_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_019d884e-17de-73a2-b422-0eacb1460f39_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019d884e-17de-7d8f-8ab0-3db6bfdd16e1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_019d884e-17de-74df-bce7-bfac9707b69d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019d884e-17de-7533-9085-938b2b17e840_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019d884e-17de-7e3c-9cdd-7fb70a59f657_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019d884e-17de-7ee9-9afb-1f45bca512d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019d884e-17de-761e-aa24-0b47196e0839_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019d884e-17de-7c83-8d4a-f49586c4bb26_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019d884e-17de-77b1-8b2a-47f3f6e543d3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_019d884e-17de-7c66-a9b0-e37f289af9d1_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019d884e-17de-71cc-8971-0427ddc06709_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_019d884e-17de-73e4-bd85-b26d1aa62484_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019d884e-17de-7895-af7c-1be5cee00711_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_019d884e-17de-7de8-9417-4ab8541ed5de_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019d884e-17de-76e5-8002-54dede761bb4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019d884e-17de-7485-8e44-d1a0d4f8e4c6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019d884e-17de-77f0-82e4-11f92a1f2906_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019d884e-17de-7f38-9d38-997a9e12d82f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019d884e-17de-71fd-a38d-de32842849d8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019d884e-17de-7d9c-9a1d-516f5b8a275d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019d884e-17de-7dab-abe0-365ff6d53216_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019d884e-17de-7efb-9dd9-e81f0e408606_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>avtx-20260513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d884e-17de-7c58-b5b5-b6da95e6fa21,g:c64acb00-4d7d-4d2e-ae32-34da6feee8cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CoverPageDocument" xlink:type="simple" xlink:href="avtx-20260513.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019d884e-17de-7ada-a7dd-6fee8d8758e1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d884e-17de-7ada-a7dd-6fee8d8758e1" xlink:to="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_019d884e-17de-70b9-98fe-1386bbf65561" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_019d884e-17de-77f8-8dce-cd1ba51951dc" xlink:to="loc_dei_AddressTypeDomain_019d884e-17de-70b9-98fe-1386bbf65561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_019d884e-17de-7b20-b871-2763370e5b19" xlink:to="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019d884e-17de-728e-b38a-b6d19555f0ed" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressStateOrProvince_019d884e-17de-728e-b38a-b6d19555f0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019d884e-17de-7dc9-ab2b-16c9b19ab947" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressCityOrTown_019d884e-17de-7dc9-ab2b-16c9b19ab947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019d884e-17de-794d-9b8b-0f7436a93513" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressPostalZipCode_019d884e-17de-794d-9b8b-0f7436a93513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019d884e-17de-7508-b6b0-5b3064f8fd27" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_DocumentType_019d884e-17de-7508-b6b0-5b3064f8fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019d884e-17de-7a7b-b251-4db13e33cee8" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_DocumentPeriodEndDate_019d884e-17de-7a7b-b251-4db13e33cee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019d884e-17de-782e-a191-fedfa09e3751" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityRegistrantName_019d884e-17de-782e-a191-fedfa09e3751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019d884e-17de-7118-a8d1-f94e31e65ffe" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019d884e-17de-7118-a8d1-f94e31e65ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019d884e-17de-74ad-9764-98a8bd5febd5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityFileNumber_019d884e-17de-74ad-9764-98a8bd5febd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019d884e-17de-7dda-b838-6f9707719d02" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityTaxIdentificationNumber_019d884e-17de-7dda-b838-6f9707719d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019d884e-17de-7f70-b7a9-94e6e855721a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityAddressAddressLine1_019d884e-17de-7f70-b7a9-94e6e855721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019d884e-17de-7910-a5ce-ad4ec8ace0e9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019d884e-17de-71e9-a602-044821929db1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019d884e-17de-7651-9f74-2f69d3054d1c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019d884e-17de-75a2-bc3f-013016620f98" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_CityAreaCode_019d884e-17de-75a2-bc3f-013016620f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019d884e-17de-7079-a2cc-ec0ddcc5f6a5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_LocalPhoneNumber_019d884e-17de-7079-a2cc-ec0ddcc5f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019d884e-17de-7582-aa19-9b75b349f0c5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_WrittenCommunications_019d884e-17de-7582-aa19-9b75b349f0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019d884e-17de-7710-99ac-cce8976c1368" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_SolicitingMaterial_019d884e-17de-7710-99ac-cce8976c1368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019d884e-17de-7523-8707-9678109b27db" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_PreCommencementTenderOffer_019d884e-17de-7523-8707-9678109b27db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019d884e-17de-7f1c-813d-5b032efad680" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019d884e-17de-7f1c-813d-5b032efad680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019d884e-17de-715b-9ed2-cef93879312b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_Security12bTitle_019d884e-17de-715b-9ed2-cef93879312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019d884e-17de-7d7d-8aa5-a4245e73f282" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_TradingSymbol_019d884e-17de-7d7d-8aa5-a4245e73f282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019d884e-17de-7590-b18d-d2984fdfeae2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityEmergingGrowthCompany_019d884e-17de-7590-b18d-d2984fdfeae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019d884e-17de-7d56-a9a4-0e0643f6ff4e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_EntityCentralIndexKey_019d884e-17de-7d56-a9a4-0e0643f6ff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019d884e-17de-7f45-b12b-602b3af53034" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019d884e-17de-7b28-a83e-48776bd35580" xlink:to="loc_dei_AmendmentFlag_019d884e-17de-7f45-b12b-602b3af53034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>avalo-logoxblk1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avalo-logoxblk1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!&17AI9@  34T *@    @ ! $2  ,
M   !  $  %$0  $    ! 0   %$1  0    !   N(U$2  0    !   N(P
M  #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)
M" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" .8!W8# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\,?\
MP4'_ .3^?CC_ -E U[_TXW%>/U[!_P %!_\ D_GXX_\ 90->_P#3C<5X_0 4
M444 ?U^?\&N7_*"CX%_]Q_\ ]2#4Z_0"OS__ .#7+_E!1\"_^X__ .I!J=?H
M!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!_#'_P4'_Y/Y^./_90->_].-Q7C]>P?\%!
M_P#D_GXX_P#90->_].-Q7C] !1110!_7Y_P:Y?\ *"CX%_\ <?\ _4@U.OT
MK\__ /@UR_Y04? O_N/_ /J0:G7Z 4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?PQ_\
M%!_^3^?CC_V4#7O_ $XW%>/U[!_P4'_Y/Y^./_90->_].-Q7C] !1110!_7Y
M_P &N7_*"CX%_P#<?_\ 4@U.OT K\_\ _@UR_P"4%'P+_P"X_P#^I!J=?H!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!_#'_P %!_\ D_GXX_\ 90->_P#3C<5X_7L'
M_!0?_D_GXX_]E U[_P!.-Q7C] !1110!_7Y_P:Y?\H*/@7_W'_\ U(-3K] *
M_/\ _P"#7+_E!1\"_P#N/_\ J0:G7Z 4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/K7OGPI_X+%_M4_!2>-O#O[07Q8ACA(9+:]\17&HVJ8)/$-RTD?)/(V\]\T
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MQ7C] !1110!_7Y_P:Y?\H*/@7_W'_P#U(-3K] *_/_\ X-<O^4%'P+_[C_\
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M<A))^:" I&V,G&5.!P,#BOG.B@"26=KB5I)&9Y')9F)R6)ZDFHZ** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?*/_!4?_@L1\)/^"1_A/PS
MJ'Q.7Q1?7WC,W:Z)I>A:>MS<7OV7R?/):1XXHU7[1#]^0$[_ )0V#CZNK\ ?
M^#YS_FUW_N:__<+0!YW^U;_P>J_$[QE)=V/P;^%_A?P39,Q2/4_$5Q)K%^R=
MG6)/*AB?V;SE'/7J/S>_:>_X+$?M._M@M<1^/OC5XYU+3[DGS-,L[W^R]-<=
M,&UM1%"V!Q\R$]?4U\S44 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5]1?L3_ /!97]I'_@G_ '-G%\.?BAK]OX?LR /#FJ2_VGHK)QE%M9MR
M19P 6A\M\=&%?+M% '])G_!/G_@\I^'/Q6EL= _:$\*3_#;6IG6(^(M#234-
M"D)'+RPDM<VPSP OV@=RRBOV,^%?Q:\,?'/P%IOBKP7XBT?Q5X;UB+SK+5-*
MNTNK6Y7IE9$)4X.01G(((."*_@GKZ!_8*_X*;_&C_@FM\0O[?^$_C"\T>*XD
M5]1T:XS<Z/K '&+BV8[&.,@2+MD4$[74\T ?V]T5^;?_  1Z_P"#D?X3_P#!
M35M/\&^)%M?AC\8I@(DT*\NMUCKKCO87# ;V/7R'Q(,D+YH4O7Z24 %%%% !
M1110 4444 %%%% !7\8?_!=3]A9?^"?'_!3/XC>";"S^Q^%=4NO^$D\,JB[8
MUTV\+2)&@P/EAD\VW_[=SUZU_9Y7XP?\'EG[#/\ PMC]D+PC\<M)M=VK_"O4
M/[,UET7YI-*OG5%=CU/E78A"C@ 74IH _FBHHHH *_9G_@S8_;E/P?\ VQO%
M7P0U:\,>B_%C3S?Z1&[';'JUBCR%5'1?-M3/N/4FVB'I7XS5W7[-_P =]<_9
M?_: \%_$;PS-Y.O>"-9M=:LB6^5Y()5DV-ZH^TJP/!5B#D&@#^\*BN+_ &??
MC?H7[2_P,\'_ !"\,W'VKP_XVT>VUNP<D;A%/$LBJX'1UW;67JK*0>17:4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M55U+4+?2+"XN[J:&UM;6-IIIIG$<<**,LS,> H ))/  H _"3_@]-_;F_L;P
M5\./V=]'O=MQK4G_  F/B2.-B&^SQEX+&)L<%7E^T2%3T-O$?2OYZ*^CO^"L
M7[:\_P#P4(_X*$?$SXI>=-)I.MZJUOH22C:8=+MP(+-=O\+&&-'8#^-W/)))
M^<: "BBB@#UC]AS]E;6/VW_VN?A[\*-#+1W_ (XUF'3FG"[OL=OG?<7!'/RQ
M0++(>.D9K^XCX;?#W1_A)\.]!\*^'[./3M!\,Z=;Z3IMK']VUMH(EBBC'LJ(
MH_"OY]_^#+;]AEO$OQ.^(G[0NL6.ZS\-0?\ ")>&Y'4[3>3*LM[*I[-'!Y,>
M><B[<=J_HDH **** "BBB@ HHHH **** "OR=_X*$_\ !VQ\&/V-/BAXP^'O
MA/P7XP^)'CCP7J=UHFHJY31])@O;:5H9HOM$@>5MDB.,K 5;;\K$$&OUBK^(
M/_@K%_RE-_:6_P"RJ^*/_3O=4 ?9'[4__!W%^U?\>'N+7PC?>$_A)I#@QJF@
M:8MU?,A_OW-WYI#?[421$<=^3^>_QX_:H^)?[3^N_P!I?$;X@>,?'-[OWK+K
MFKSW_E'I\@D8A !P H  X'%>?T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!J>$_%^K> O$5IK&A:IJ.BZOI[^;:WUA<O;7-L^,;DD0AE.">0
M1UK]*/V$_P#@ZZ_:<_9)DL=+\::C:?&[PG;X1[7Q,Y35ECZGR]10&4N?[UPL
M_!/'3'YAT4 ?V$_\$W_^#BG]G+_@HS)I^AV'B)OA_P#$*\"I_P (OXG=+6:Y
ME/&RUN,^3<Y/W55A*1R8UYQ]YU_ '7ZB?\$F_P#@Z%^,G[!=QIOA/XCS:A\7
MOA7 4A^S:A<E];T6(8'^B73G+JJ]()B5PH5&B&30!_5Q17C?[$O[>7PL_P""
MAWP9M_'7PI\4V?B327817<'^JOM)GZF"Z@/SPR#J PPPPREE(8^R4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!_#'_P %!_\ D_GXX_\ 90->
M_P#3C<5X_7L'_!0?_D_GXX_]E U[_P!.-Q7C] !1110!_7Y_P:Y?\H*/@7_W
M'_\ U(-3K] *_/\ _P"#7+_E!1\"_P#N/_\ J0:G7Z 4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !117E/[:O[7/A7]A']EKQI\6/&<LW]@>#;$W<D
M,)437TK,(X+:+<0/,EE>.-<D#+@D@9- 'JCR")&9B%51DD] *_+C_@J7_P '
M3OP2_8:.I>%OAN]M\9OB5;EH7@TR["Z'I,HX_P!(O%R)&4GF* .<JRN\1K\4
M/^"I?_!QE\>/^"EOV[PZE^?AG\+[DE/^$6T&Z?=?1\\7UUA7NLYY3"0G"GR]
MPW5^?= 'T3^W]_P5*^-O_!3#QV-9^*WC*[U.RM9&DT[0;3-KHNDY[06RG:&Q
MP9'+RL  SM@5\[444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?27_!/O\ X*Q_'+_@F9XP_M#X6^,KFSTF>;SK_P .ZANN]#U0XP?-
MMBP 8@ >9&4D & X%?-M% ']8?\ P2D_X.?/@S_P4&N-+\'^-?)^$?Q4O"L$
M6G:E=!M)UF4X %I=L  [-TAE"N20J&4Y-?IS7\ =?KE_P1Z_X.IOB+^QDF@_
M#[XU+>_$SX6682S@U(MO\0>'H!PHCD8@74*#CRY3O"X"R!46,@']15%<3^S_
M /M">"_VJ?A'HOCSX>^(M/\ %7A+Q!#YUCJ-D^Z.0 E64@X9'5@59& 964@@
M$$5VU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOWH^"_\ P9 :]=_9YOB)\>])T_:09K+PYX<DO-X[A;B>:+;]3"WTKZJ^$O\
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M3^T9\#-#_:<^ WC'X=^)(VET'QMHUUHU\% W)%/$T9=<]'7=N4]F4'M7;44
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MXMMXL^+3_P#"&Z6%?$D<,Z,;Z8#K@6JRQ[AC:\\1SG /Z*5_*W_P=R_MR?\
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M@_\ @K%_RE-_:6_[*KXH_P#3O=4 ?/\ 114UK;27ES'##&\DDC!$1%W,S'@
M#N3Z4 0T5]-?L^_\$;_VIOVI/LTG@OX$_$.^L[S'D7]]IATJPF![K<W9BA(]
MP^!7VI\#/^#-G]J'XB".;QAKGPU^'EJ0/,BNM4EU*]7/HEM&T1QWS,.V,\X
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M$_QXMK_Q%\ M6;X2^+&1I%T.\>2\\.WTF.%&2T]IN/5D,B*,!817X ?MM?\
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MLMO)C@2PRJ\3@$@-&V"1S7IM !1110 4444 %%%% 'QW_P %W/V%5_X*#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-4O"NC_$G3FUO186/":I9)F54'K+:>8S'_IS3WK^E"@ HHHH **** "BBB@
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M-4@M+8,-P@MXXX]WS$,Y+'TC3-/@T>PM[2UAAM;6UC6&&&) D<**,*JJ. H
M  '  JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 UXUD0JP#*PP01P17XL?\%Z/^#8/P_\ M!>'M6^+'[-_ARS\
M/_$B%VO-8\)V;+;:=XE3!+R6T9PD%WG!VJ5CE^;@2'<_[4T4 ?P+^+/"6J^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!T__P $W(_V(/\ @H)-XV\.Z>MGX"^-0FUZR2)-L-EJ:LO]H6X'8&21)P.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH]\2_B/;W#3>'KC43I?AP9^5=+M?W%LP'\/F*AF89(#S/7RU0 4444 >Z?\
M!-;]CR]_;Y_;G^&OPGLUF\GQ9K$<6I30\-:Z?$#->3 ] 4MXY6&>K #O7]O'
MAKPY8^#O#NGZ3I=G#8Z9I=M'9V=M"FV.WAC4(D:CLJJ  .P%?@K_ ,&6'["R
MI9_$;]HG6;+YI&_X0WPS)(O0#9/?RJ#ZDVL:N/[LZYZ@?OU0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!6O[&'4[*:UN88KBWN$:*2*5 Z2HPP58'@@@
MD$'K7\.O_!1']F=OV-?VY_BM\,3')';>#?$UY8V'F?>DLO,+VLASG[]NT3=3
M]ZO[DZ_EH_X/&?@*OPP_X*I:?XPMX56W^)7A"QU">4+CS+NU:2R<'U(@@M>?
M1@.U 'Y-4444 %?T<?\ !DC\=I/$'[-WQL^&\UPC#POXCLO$-M$Q^?;?VS02
M;?\ 9!T].!P"_;=S_./7[$?\&7'Q6?PO_P %'/'WA.2;9:>+/ <\ZID?O+FU
MO;5D]^(I;@\?EW !_3I1110 4444 %%%% !1110 4444 %%%% '\,?\ P4'_
M .3^?CC_ -E U[_TXW%>/U[!_P %!_\ D_GXX_\ 90->_P#3C<5X_0 4444
M?U^?\&N7_*"CX%_]Q_\ ]2#4Z_0"OS__ .#7+_E!1\"_^X__ .I!J=?H!0 4
M444 %%%% !1110 5Y_\ M4?M Z3^RE^S7X\^)>N*TFE>!="O-;N(E.&N!!"T
M@B7_ &G8!![L*] K\4/^#L+]KS6/B-K7PK_8\\"ZA]CUWXFZI::GXC=KE8(6
MM3/Y5G;2EB 8FGS.Y;"C[)&<GY@ #PWX8_M?>,/V.?\ @E5\2OVNO$$-]'^T
MM^TLUPOAG7I=.A:W\.:+]L,8:V5AE0]PSRE0&4O<63L@7!;\BOV-](C^+7[8
M?@*'7M#U;Q_-K/B&T@&AVTA%SXBG:11%9&7>AB$[[(VE)^1&=@"5 /KW_!:'
M]KW3_P!H[]J:+PKX1L;SP_\ #7X.Z39>!_#^D/J ND3^S[=+26X9HV:%Y&:+
M9YD7RO'#$<GJ:O\ P1W_ &>Y/VE/VW?!G@?3]0NK?Q1XAU&'2K%K)?WVFV,J
M32ZIJ4<I!C26UL8[@1Y&]9[F)UYA. #^AK]C3]F*Z_9[\6^+/VB_BMXHTV[F
MT"UN?$OBC4(%BVW=]:V%U%<WMME%V6+->ZG;P1KM41:9;R R/<W#M^*G[<__
M  5@\7?M!?MP>%_VH=>T/Q)J7@G1?$5W'\*]&UB>*.RMH[*>.0W(A$85MI:T
M9AB0/-&P>7$82OK/_@YR_P""JBZ_)?\ [-/@U;S03XFU2";Q;K-S&RV\VCVI
M5=/MX9%W--:NZRW;NH&,A5#Y<GYX_P""+W[.<G_!2/\ X+/^%OL?B&W;X>_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?@[_P 'O_PG6]^&_P
M/'4<>TZ;J6KZ%<2#/S_:(K:>)3QCC[-,1R/O'KV_>*OR7_X/*/ __"3?\$G]
M#U)8]S^&_B#IMX7&T%$>TOK<CGG:6F3A><A3T!H _EKHHHH *_0G_@UQ\>-X
M(_X+<_"&+S&CM]>BUC2YR"WS!]*NW08'7,L<77('7L"/SVKZP_X(7>)7\*?\
M%?\ ]G>ZC^]+XUL;/[^SB=C >?I(>._3O0!_:91110 4444 %%%% !1110 4
M444 %%%% '\,?_!0?_D_GXX_]E U[_TXW%>/U[!_P4'_ .3^?CC_ -E U[_T
MXW%>/T %%%% ']?G_!KE_P H*/@7_P!Q_P#]2#4Z_0"OS_\ ^#7+_E!1\"_^
MX_\ ^I!J=?H!0 4444 %%%% !1110!F^*_$UCX)\,ZEK6JW"V>EZ1:RWMY<.
M"5@AC0N[G&3@*I/ SQ7\D_[:O[:$GQS_ ."H'[3G[1.FF.UL?#HOM!\-30(,
MF9K8Z%IUPCY 2<0F2^5EW.K6SE<;0P_H7_X. _VQ]4_8<_X)6_$;QAX?GL(/
M$FH&TT#3!=[2LK7ES'%.%4D%G%J;E@%R04W8PI(_D3\1:O=:!\$=,T59#;VN
MN:DVI7%HTQD,QMD,$$^.BKNFO5 '.0_)&V@#AK<R"=/+W>9N&W;][/;'O7[7
M_P#!NK\)]%_8?_X)^_M#?MT>(9+6\UKPOI%YX;\(0N\H*7852XE3&U_M-U-8
M0HV25"RY +5^*EG9R7UU'#!')--,P2.-%+-(Q.  !R23Q@5^RW_!9/65_8*_
MX(C_ +/O[/\ I-]>3:I\1[:.Y\78N2UK%=:5<327]JL.U/+D35+K#NR[I&M_
MF+,F: /R>_:#_:%\5?M1_$=O$GBN^FU#4C!#86L0+>38VL2A(;6!"3LC0 X4
M=2S,<LS$_P!$W_!KOX>^"?P2_P"">?A'QKHMCH]Q\6/B=XKD\&WFHK&?[82X
M0&5K;$@=8TAM_,GQ$-DD8B:3#DA/YY/V3?V:?$G[8G[2'@GX8^$8?M'B'QMJ
MT6F6P*;EMU8@R3N/^><48>1SV6-C7].7_!";]G?PSXY-IXNM_!?AOPKH?P!B
M?X?>&-.TC6I-2AB\0?9XT\2:OYJXBF:Z8VT"O\Q"VTK @S-0!^G-C;R6ME#%
M)/-=21HJ-+*%#RD#!9@H"Y/4[0!SP .*LT44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B)
M_P 'CG_!-N'XD? K0/VD?#>GLWB#P*\6A>*/)C'^D:3,[""X?N3!<.J9_NW1
M)XC%?S?5_>9\>/@OH/[1OP5\5^ ?%5FM]X=\9:7<:/J,) RT,\;1L5)^ZP#9
M5NJL 1R!7\,O[07P9U3]G7X[>,OA_KB[=8\$ZW>:%>_)MW2VT[PL0.>"4R.3
MP1R: .-HHHH *]$_92^/>H?LL_M-_#[XDZ9YCWW@3Q#8Z['$C[#.+>=)6B)_
MNNJE"#P0Q!XKSNB@#^^'X<^/M)^+'P^T'Q3H-Y'J&A^)=.M]5TZZ3[MQ;3QK
M+%(/9D93^-;=?FE_P:E_M</^TU_P25\.Z%?W1N-<^$NHW'A&XWOND:V3;<6;
M8[*L$Z0KV_T<^AK]+: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBOG']J7_@K?^S;^Q8]Q!\2/C)X*T/4K5BLVE07G]HZI
M$1V:SM1).OIDH!F@#Z.HK\9_VB/^#TWX$^ 9KFU^&_PX^('Q$N;<D)<7TD&@
MV%Q[J[>=,!_O0*?:OAOXZ_\ !YS^TAX\:>#P1X/^&?@&SDSY<K6D^K7T7/'[
MR6183CW@H _I\J&YN8[.VDFFD2..-2[N[;54#DDD] /6OXS?C%_P7Z_;'^.4
MTC:O^T#X\T\2$?+X>N(_#ZJ!T ^PI"?ZGOFOF?XC_'3QM\8KCSO%WC#Q3XJE
MR&WZQJL]\V1P#F5VH _MX\?_ +=WP0^%#NOBGXR?"GPTT9VN-5\6V%F5.<8/
MF2KCGCZUX_XO_P""\'['O@<R?;?VA?AO-Y:ES_9^H'4<@'''V=7R?89..>E?
MQ=T4 ?V":[_P<Z_L-Z!.\,GQQMYY$3>!;>%M;N%;T =+,IG\>.^*YC_B+ _8
ME_Z*-X@_\)+4_P#XS7\D5% ']8>I_P#!W'^QG8WTD,/B3QQ>1J<":'PM<".3
MCL'VM[<@5M?\18'[$O\ T4;Q!_X26I__ !FOY(J* /ZY-,_X.K?V(=2O%AE^
M*6K:?&P),UQX0U9HUX[B.W9N>G KIM#_ .#F?]AWQ \@M_CM8Q^6 3]I\-:U
M:@Y]/-LUW?AG%?QZT4 ?V@>&O^"]?['7BSR?LO[0WP[B\Y/,7[9>/98'^UYR
MIM/L<'VKTGP;_P %-OV</B!)$FA_'[X,:M-,$VPVWC339)LO]T&,3;E8GC:0
M#GC&:_AVHH _OB\(?$/P_P#$&U^T:#KFCZY!C=YEA>1W*8R1G*$CJ"/P-;5?
MP%Z?J%QI-['<6L\UM<0G<DL3E'0^H(Y%>O?#?_@HA\?O@VL:^%/C;\6?#L4.
M-L.G^+;^WA(&, QK*%9?E'!!' H _N6HK^/CX2?\',/[:GPC:&.'XS7FOV<9
M!:WU[1K#4?-P>C2R0^=STXD'Z#'U7\$_^#UCXZ>%'MX_'WPN^&OC*UB_UCZ9
M+=Z+=SCW<O<1@^XB QCC/) /S%_X*)Z*_AG_ (*!_'339+=;633_ (A:_;-"
MH&(2FI7"E1CCC&...*\9KT3]K'XXK^T]^U/\3/B4-+;11\1/%>J>)AIQN/M/
MV#[;=RW/D^;M3S-GF[=^U=VW.T9P/.Z "BBB@#^N[_@U>UQ=6_X(<_!^W6-E
M;2[G7;9B?XR=:OI<C\)0/P-?H=7YP?\ !J!_RA+^'/\ V%=;_P#3G<5^C] !
M1110 4444 %%%% !1110!\L?\%F?V&H_^"B'_!./XD?#B&U$_B*33VU?PT<?
M,FJVN9K90>WFE3"QP<)._>OXKIH&MI6CD5DD0E65A@J1U!%?W\5_'[_P<G?L
M-?\ #$/_  53\;QZ?8_9?"?Q)/\ PFFA^6I$:K=NYNH1V7R[M;@!!]V,Q< $
M"@#X%HHHH DBG:WE62-F21"&5@<%2.A!K^U/_@C-^V['_P %"/\ @F]\,_B-
M/<?:/$$VFC2?$8+9==4M/W%RS#)QYK()E!).R9,U_%17[B?\&7?[<W_"#?';
MQ]^S[K%]Y>G^.+;_ (2?P]%(P"KJ-J@2ZC0=2\MJ$<^BV)Z=P#^CBBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#SC]K?]H_1?V0/V9/'GQ0\0G.D>!=$N
M=7FB#!6NFBC)2!2>-\K[(U_VG%?PY?&+XL:U\=_BUXG\;>)+K[9X@\7ZK=:S
MJ4X! EN+B5I9& ). 6<X&>!Q7]#?_!Y[^W/_ ,*\_9R\"_ /1[W;J?Q"O!XB
MU^*-AN73+-\6\;C^[+=_.I'>Q/3O_-Y0 4444 %?UL_\&MW["J_L=?\ !+CP
MYK^I69@\6?&*0>+M19A\Z6DBA=/BSQ\HM@LN".&N9!SQ7\UG_!++]BRZ_P""
M@_[>_P -/A3#'(VF^(-6276I$)4V^F0 S7CAA]UO(CD"],NR#.2*_MJTC2K;
M0-*M;&RMX;2SLHD@MX(4"1PQJ JHJC@*   !T H N4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%97C#QIH_P]\/7.K:]JVEZ'I-
MFN^>]U"Z2UMX%]6D<A5'N37PU^U!_P '+_['?[,,EU:R_%&'QYJUJ2#8>#+1
M]8\S']VY7;:'T_UXZ_6@#[ZHK\"OV@?^#W>SC,UO\*O@7=7&<^5J'BS6UAQS
MQNM;9&SQZ7 Q[]:^+/C9_P ':W[9'Q;$R:3XF\&_#V&7(*>'/#<+$+Z![TW+
MCZ@@^XH _K(K'\7^/=#^'^G?;->UK2=$M?\ GO?W<=M'V_B<@=Q^8K^)_P"+
M7_!5_P#::^./F+XH^/7Q8U*WF(+VB^)KNWLR1D9\B)UBSR>=O>O!]8UR\\17
M[W>H7EU?74F-\UQ*TLCX]68DF@#^W'QK_P %5?V9?AW*T>M?M!_!>QN(R UN
MWC+3VG&21_JUE+XR#SC'%>5>)O\ @XB_8L\*OMN?C_X3E^4M_H=K>W@P.O,,
M#\^@ZGM7\:]% ']=VM?\'4/[#NE11M!\8+[4V8X*VW@_6E*>Y\RT0?D36/>_
M\'8G[%%I9R21_$#Q)=/&I811^$]0#R'T&Z(+D^Y ]Z_DIHH _K)T7_@[:_8Q
MU>X>.X\6>,M-5%W"2Y\*W3*Y]!Y8<Y[\@#CK6I_Q%@?L2_\ 11O$'_A):G_\
M9K^2*B@#^O#2/^#IS]AO5+3S)OC'=Z<^XKY5QX.UMG(]?W=FZX_'/'2NLT#_
M (.//V)_$AMUM_CYX=C^U#*?:M+U*TV\9^;S;9=GT;'IUK^..B@#^UKPK_P6
MM_9'\8F'['^T9\(8?M!;;]N\26UAC;G.[SV3;TXW8SQC.17J'@?]M[X+_$T1
M_P#"-_%WX8>(?-V;/[,\4V-WOWYV8\N4YW8./7!K^%6B@#^_2QOX=2M([BVF
MCN()E#QRQN'1P>A!'!'N*L5_!#X+^)OB3X;W7VCP[X@US0;C.[S=.OI;5\XQ
MG,; ].*]^^&'_!9C]JSX/2PMH?[0GQ96.W(:."_\17&I6Z<YP(KEI$QGJ-N#
MD\4 ?VP5^:__  =CZ;!??\$4_'<LT>^2SUK19H22?W;F_B0G_OEV'/K7XO?"
M#_@[5_;,^&30_P!K>*?!OCZ*%0/+\0>&;= X&>&:R^S.<\ G=DX'.<D]1^WU
M_P '37B[_@HI_P $_/'7P3\:?"/PWI.H>,CIY37]'UF:.&R^RZA;7G_'I+'(
MS[Q;E,^>N-^><8(!^4E%%% !7O7_  2RU&#1O^"G/[.5Y=2"&VM?B?X:FE<@
MX1%U6V+'CG@ UX+7L'_!/C_D_GX'?]E T'_TXV] ']SE%%% !1110 4444 %
M%%% !1110 4444 ?PQ_\%!_^3^?CC_V4#7O_ $XW%>/U[!_P4'_Y/Y^./_90
M->_].-Q7C] !1110!_7Y_P &N7_*"CX%_P#<?_\ 4@U.OT K\_\ _@UR_P"4
M%'P+_P"X_P#^I!J=?H!0 4444 %%%% !116?XETN;6/#]_9VUR]G<75O)#%<
M(2&@=E(#C!!R"0>".E '\\/_  >%_M=:I\6_#_[.7A"'39+#0]:TBZ\>O$[E
MO.$S"&T#!3D-' LK-Q_RW(XVFOP]U=Y#?R)))YGD?NE(.Y=J_*,'TP.O?K7Z
M(_\ !S;\5['QU_P5H\4^$+-O.\-?!_PYI'@K1XX6'^CQ06T=Q*H &-R37,ZG
MIC9Z#%?G%0!]&?\ !*3PEH/B7]OSX?ZGXL?;X1\!W%QXZUQ=L;?:++1;:759
MH-KLH;S5M/*(!+8D) 8C![+_ (+6?'3Q!\8_VS9-+\22;M6\!:/;Z)J4:NK1
MKJLC27^JLNWCY]2O;UL'YER$/W*XO_@G'::M<_$_6K.QT^WN=.\0VVF>&]4N
MKJ[-K:VEO?:[ID+AWP0?,3?&5/1'D?!\LBO)OV@?B?=_&[X\^-O&FH7'VR^\
M7Z_?ZW<3D%3/)<W$DS/@\C+.3@\\T ??7_!*'X/^(/V1OV!_B]^UY:[M+\6)
M<Z9X$^%L['RI;C4;S4(H[Z>)BP8*MLDL)9%)97N%5U*/C^F+_@G?^QWX;_8.
M_9 \&_#/PK^\TS0[-7DN6BBCDOKB3#RSR&,L&>1R6+;WZX!VA0/YR/AYJB^,
M_@/^PO\ LG>&8(Y=4\9>,(_&_B#4+O<FF7<=_(?LUN&9=SM;V]S=)*J@*75<
M"0L"O]4%M;1V=M'##&D<<:A$1%VJH'   Z >E $U%%% !1110 4444 %%%%
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MJ>&+AA_ ##]N3\Y;&)?;=GM7]:E !1110 4444 %%%% !1110 4444 %%%%
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MX)T:&RN)X@0M[=G,EU<\\_O;AY9,=M^,#I7L5 !1110 4444 %%%% !1110
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M;Q13):Z5:Z=:F]%G$DH\P+$\*VJ;P&"11 XVC']5U?S?_P#!HI\*?$'[2_\
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MM>WC:;]H;PY'(R@NJ>$IF56[@'[4,CWP,^@K^B"B@#^>'_B!U\5?]'$>'_\
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MHH **** "BBB@ HHHH **** /X8_^"@__)_/QQ_[*!KW_IQN*\?KV#_@H/\
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M<9# O#-=VQ!==JF0.3\F#\SRD#3H-JJK!W#$#YF^[U_/&/8^IKWK]C+XO?\
M"&_!7]H/PO,\#6_BWP(1!'--# K7$&HV4@Q))RI\KSF"(0TK1QQ@$L, '[$?
M\&.)E'A;]I;<UUY/VOPWL5E_<AMFJ;BI_O8V[AV 3UK][J_G-_X,P_VDX? _
MQ;\=?#6&UFOKCQU(M[>E$&=.2TMY'MY\[LF)B;F)_E.UY+49&_!_HRH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG\_''_LH&O?^G&XKQ^@ HHHH _K\_P"#7+_E!1\"_P#N/_\ J0:G7Z 5^?\
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M^&@?^"OG[/\ X?95DCA\6V^N2HRAEDCTU7U%U8$$%66U((/4$U_:-0 4444
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M*4DQWEDAY(1UK^FV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /XX_^#D'_E-I\?/^PK9?^FRTKX?K[@_X.0?^4VGQ\_["
MME_Z;+2OA^@ HHHH _K=_P"#4#_E"7\.?^PKK?\ Z<[BOT?K\X/^#4#_ )0E
M_#G_ +"NM_\ ISN*_1^@ HHHH **** "BBB@ HHHH **** "L/XD_#W1_BW\
M.]>\*^(+./4=!\3:=<:3J5K)]VZMIXFBEC/LR.P_&MRB@#^%G]MS]EK5_P!B
M?]K?XA?"G71*U_X'UJ?35F==OVRW#;K>X _NS0-%*O3Y9!7E-?NE_P 'HW["
MA\*_%OX??M"Z+8LMCXKM_P#A%/$DB(=B7MNK26<KG^]+;^;'V %FG<FOPMH
M**** /ZHO^#1K]N;_AIC_@G!)\-]4O/M'B;X)W_]D[7;,CZ5<;YK)S[*1<0
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M?_1L= '\8=%%% !7L'_!/C_D_GX'?]E T'_TXV]>/U[!_P $^/\ D_GX'?\
M90-!_P#3C;T ?W.4444 %%%% !1110 4444 %%%% !1110!_#'_P4'_Y/Y^.
M/_90->_].-Q7C]>P?\%!_P#D_GXX_P#90->_].-Q7C] !1110!_7Y_P:Y?\
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M10!:TW4)](U""ZM9IK6ZM9%EAFB<I)$ZG*LK#D," 01R"*_MD_X).?MKP?\
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MI\.[JU:Z\-MJ U?Q)Q\BZ7:?OKA6/;S0JP \_-.M?VG0P+;0K'&JI&@"JJC
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MBBB@ KX__P""_'_*&W]H3_L59?\ T;'7V!7Q_P#\%^/^4-O[0G_8JR_^C8Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;GNQ^M?H16?X;\.V/A#PYI^DZ7:PV>FZ7;1VEI;Q#"00QJ$1%'HJ@ ?2M"@
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MRA+^'/\ V%=;_P#3G<5^C]?G!_P:@?\ *$OX<_\ 85UO_P!.=Q7Z/T %%%%
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M]SE%%% !1110 4444 %%%% !1110 4444 ?PQ_\ !0?_ )/Y^./_ &4#7O\
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MM_\ P9N?'./X<?\ !4'7/"%S(JP_$3P;>6ELF<%[NUEANT^N(([KC&>AZ Y
M/ZC:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHJO>7D=C:R33RQPP0J7DD=@JQJ!DDD\  <Y- '\7_ /P7:UR#Q#_P6#_:
M'N+?=Y<?C*[MCD?QP[8G_P#'D:ODNO0/VKOB[_PT#^U%\2O'FYF_X3;Q5JFO
M[BNTM]JNY9\X[?ZSIVKS^@ HHHH _KI_X-5M%DTK_@A_\*+AV5EU*]URYC"]
M44:Q>18/OF(GZ$5^B=?'?_! /X?R?#+_ ((W?L]Z;)&T;7'A9-6P1U%[-+>
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M+K0VFN76.'5X$,;(B8*F6[1ER25!-L@') 8 _I2HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY??\
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M+U^MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\>_\%X_VO(_V+O^"4_Q=\51W*VVM:OH[^&=$PV)&O=0_P!&1X_5HDDDGYXQ
M >O0_85?S2_\'B?_  4;M?CC^TKX<_9_\-7GGZ'\*BVI>(GC;,=QK,\8"1>A
M^S6[$9'1[J92,I0!^+M%%% !5S0]%NO$NM6>G6-O)=7VH3I;6\*#+32.P55
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M6=BS,S$ ROVSOVPO&W[>7[2?B?XI?$#4&OO$7B:Y\PJN5@L8%^6&VA7^&*)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@H)^T+K7Q*^)FM-JWB#5FV11)E+32[923':6T>3Y<*9.%R2269BSLS'R*@
MHHHH *_HN_X,MOV&)O!GP?\ B%^T'K-F\-QXSF_X17PX\B;2]A;N)+R93_$D
MER(H_9K)Z_!_]C_]EGQ1^VS^TUX+^%G@ZW$_B#QKJ<=A S*6CM(SEIKB3'/E
MPQ+)*Y'.V-L9/%?VV?LJ_LW>&_V/_P!G'P7\,?"5O]G\.^"=*ATNTRH#S[%^
M>9\<&25R\CGN[L>] 'H5%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5F^+?"VG>.O"NJ:)K%G#J&DZS:2V-[:S#,=S!*A22-A_=96(/L:TJ* /X=
M/^"CW['VH?L$?MP_$KX2WWG2)X0UF6"PGE^_=V$@$UG,> -SVTD3'' +$=J\
M.K]^O^#TW]A;9<?#G]HK1[7_ %@_X0OQ(8UZD>9<6,S8]OM,;,?2!<] /P%H
M **** /ZPO\ @U&_;G_X:R_X)AZ9X/U2^^T^*O@I<CPQ<J[ R-IQ4R:=)CL@
MAW6Z_P#7FWU/OW_!<S]NC_AWO_P3.^)'CFSOOL7BC4+/_A'?##*P67^T[P-%
M%)'GJT*>;<8]+=NO2OY[/^#5W]NC_AD3_@J+HGAG5+P6_A3XS0?\(G>J[[8T
MO6;?I\N.[_:!Y YX%VYY.*]__P"#S7]N?_A9_P"U+X-^ ^CW@DTGX9V0UK78
MXWX?5;U 8HW'K#:;&4_]/K@]!0!^*=%%% !7:?L^_!'7OVEOCGX/^'OAFW^U
M>(/&NL6VBV"$':)IY5C5F(Z(N[<S=%523P*XNOV2_P"#-[]A?_A<W[:7B?XU
MZO9M+HOPCT[[)I3NGR2:O?(\892>&\JU%QD=5:>%N.,@']%O[,7[/^A_LJ?L
M\>"?AKX;C\O0_ ^C6VC6A*[6E6&-4,C?[;L"['NS$]Z[VBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O&O^"@'[(ND_MY?L:?$3X1ZPT,,'
MC71Y+2VN)5W+97BXEM;C&#GRKA(I,#D[*]EHH _@?^(GP_UCX4_$#7/"WB&Q
MGTO7_#=_/I>I6<PQ):7,,C1RQM[JZL#]*PZ_;C_@\!_X)9R_"CXUZ?\ M+>$
M--;_ (1GQY)'IGB](5^6PU9$VPW) Z)<Q(%)Q@2PDD[I@*_$>@ HHHH _7K_
M (-@?^"X=O\ L,_$QO@E\4M6^R_"?QQ>B32=3N7)B\*ZF_RY8_PVMP=H<_=C
M<*_RJ96K^H!)!*BLI#*PR".A%?P"U^VG_!OY_P '-TG[-.FZ%\$?VAM0NK[X
M?VX6R\.^,)-T]QX;3@1VMWU:2S49"2#+PC"D-&!Y0!_2116;X8\5:9XY\-V.
MLZ+J5CK&D:I EU97UC<)<6UY"X#))'(A*NC*00RD@@Y%:5 !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%->01(S,0JJ,DGH!7X/\ _!PI_P '
M-=CX:TC7/@;^S7X@^U:U<;['Q/XZTZ4&&P3[KVNG2J?GF/*O<+\L8XC+.=\0
M!XA_P=<?\%JK7]I+QJW[-_PQUA+SP/X1OA-XPU.TEW0ZYJ<3?)9HPX:"V8$L
M<D/,!Q^Y5F_%2BB@ HHHH V/ /@C5OB;XZT7PWH-E-J6N>(;^#3-.M(1F2ZN
M9I%CBC4?WF=E ]S7]P7[ G[*&F_L,_L9_#?X3:68I(?!&B0V,\T:[5N[LYDN
MKC';S;AY9,>KU_/S_P &@?\ P32F^/?[5&I?'_Q+IOF>$?A3FUT$S)F.^UR5
M/O*#PPMH'+GTDFMV!RIQ_310 4444 %%%% !1110 4444 %%%% !1110!_#'
M_P %!_\ D_GXX_\ 90->_P#3C<5X_7L'_!0?_D_GXX_]E U[_P!.-Q7C] !1
M110!_7Y_P:Y?\H*/@7_W'_\ U(-3K] *_/\ _P"#7+_E!1\"_P#N/_\ J0:G
M7Z 4 %%%% !1110 4444 %%%% !6/X^\#:/\3_!&L^&O$.FVNL:#X@LIM-U*
MQN4WPWEM,ACEB<=U9&8$>AK8HH _CC_X+G_\$@=>_P""37[4TVFVL=YJ7PK\
M7/)>^#]9D&[=$""]E,W3[1!N )_C0HXQN*K\/U_;]_P4C_X)[^!_^"FW[*VM
M_"_QQ;[8;H_;='U.-<W&A:DD;K!>1#(R4\Q@RDX='=3PV:_C;_;6_8T\=?L!
M_M'^(OAA\1-+;3?$&@386103;ZE;MDQ75N_\<,B\@]0<JP#*R@ \EHHHH *Z
M+X6?%;Q)\#OB'H_B[P?KFJ>&O$V@W NM/U/3KAK>YM)!D;D=2",@D$=""0<@
MD5SM% ']3G_!$G_@YL\"_MW:9H?PX^+]UI_@7XS;([2&ZE(ATCQ;+T#0/PL%
MP_&8&P&8_NRV?+3]8*_@#K]8O^"2/_!U)\4_V(!I?@OXOKJ?Q<^&%N$MXII9
MPWB#081@#R)W.+F-5SB&=@>%"RQJ-M ']35%>,_L7_\ !0#X0?\ !0?X<_\
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MFOY^_C/\;/%W[17Q+U;QEXZ\1:MXK\4:Y,9[W4M2N&GGG8]!D_=51PJ+A54
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MFLZ:Q_B=XV\J>)?1568^_>@#]M**^8_V=?\ @LG^RW^U9%"/!/QR^']Y=W!
MBL-0U :3J$A/9;:[$4Q].$-?2UM<QWEM'-#(DD<BAT=&W*P/(((Z@^M $U%%
M% !1110 4444 %%%% !17F'QY_;/^$?[+MK))\1OB;X$\$>6F_RM:URVLYG&
M ?DC=P[D@C 4$G-?G[^U1_P=X_LK_ R*XM?!,GB[XNZM'N1!HNFM8Z>''9[B
M[\MMIYPT44H./3F@#]4:^=_V\O\ @J;\#?\ @FWX0?4_BMXYTW2-0DA,UCH%
MLPNM:U3K@0VJ'>5+#;YC[8E)&YU'-?SM_MP?\';7[2W[4:76D^ FT?X(^&KC
M*A="S>:PZ''RO?RKE2",AK>*%NV37YB^,O&NL?$7Q-?:YX@U;4M>UK4Y3/>:
MAJ-T]U=7<AZO)*Y+.Q]6)- 'Z4?\%?O^#G'XK?\ !16VU3P1X#CO/A3\(KK?
M!-86MSG6/$$)X_TVX3&V-EZV\6$PS*[S#!'Y@T44 %%%% !7K_[#7[%WC3_@
MH)^T]X7^%?@&R^T:WXDN-LEQ(I^S:7;+\TUW.P^[%$F6/=CM50695/$?"'X0
M>*/CY\3=#\%^"]#U#Q)XJ\27:66FZ;91^9-=2MT '0 #)+$A54%B0 2/ZXO^
M"%/_  1:\._\$D/V?F;4#9ZY\7O&$$<OBG6XURD &&73[8GI;Q-G+<&5_G;
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MI_A7_P %M?VM/@S'''H?[0GQ0:*$8CBU/6I-6BC&,8"7?FJ .P P*^@_ ?\
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M\ZT %%%% !117>_LQ? #6_VJOVA_!/PU\-Q^9KGCC6;71K4E=RQ--(J&1O\
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M10 4444 %%%% !1110 4444 ?PQ_\%!_^3^?CC_V4#7O_3C<5X_7L'_!0?\
MY/Y^./\ V4#7O_3C<5X_0 4444 ?U^?\&N7_ "@H^!?_ ''_ /U(-3K] *_/
M_P#X-<O^4%'P+_[C_P#ZD&IU^@% !1110 4444 %%%% !1110 4444 %%%%
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M_3-_P2[_ ."+_P %_P#@E-X+\GP/H[:QXSOH?)U;QAJJ+)JM^#@M&A Q;P9
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MI#UD<VI1)6/K*KU^>O[1W_!DIX#UV2:Y^$_QF\4>&VR72P\4:9#JT;$_P">
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MP5P#@D9!P37#?\03'Q^_Z*M\'_\ OO4?_D:@#\8:*_9[_B"8^/W_ $5;X/\
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MQ'K7ZS_#+X4^&?@IX(L?#7@[P[HOA;P[IB>7::9I-E'9VELOHD<8"K^ KH:
M*NEZ9;Z'IEO9V=O#:6=G$L,$$,8CCAC4!515'"J   !P *M444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7&^.OV?? 7Q1\S_ (2;P1X1\1>:&#_VGHUO
M>;PV V?,0YS@9]<"NRHH \ \2_\ !*K]F+QB\S:E^SO\$+J:X4*\S>!],$Q
MX&)!"'&,=C7/?\.4OV1_^C<_@_\ ^$S;?_$U]044 ?+_ /PY2_9'_P"C<_@_
M_P"$S;?_ !-:?A[_ ()%?LK^&HRMI^S?\#N)!*'G\$:=<2*W'1Y(68=!P#@'
MGJ37T;10!YSX/_9$^%/PZ?=X?^&/P]T-MY?.G^'+.U.X@*3\D8Y( !/H*]$2
M-8T"J JJ,  < 4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNY&V1LJ5)P<@>Q4 %%%% !1110 4444 %%?D#_Q&K?LL_P#0@_M ?^"/2/\
MY9T?\1JW[+/_ $(/[0'_ ((](_\ EG0!^OU%?D#_ ,1JW[+/_0@_M ?^"/2/
M_EG1_P 1JW[+/_0@_M ?^"/2/_EG0!^OU%?D#_Q&K?LL_P#0@_M ?^"/2/\
MY9T?\1JW[+/_ $(/[0'_ ((](_\ EG0!^OU%?D#_ ,1JW[+/_0@_M ?^"/2/
M_EG7Z3?L4_M=^&_V\?V6_"/Q<\'V.N:=X;\9V\MS96NL0Q0WT2QSR0,)$BDD
M0'=$Q&UVX([\  ]8HHHH **** "BBB@ HKR?]M;]KOPW^P=^RWXN^+GC"QUS
M4?#?@RWBN;VUT>&*:^E62>.!1&DLD:$[I5)W.O /?@_FS_Q&K?LL_P#0@_M
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M"'Q8\#27S^%_&5HUU:)>HD=U;,DCQ2PS*CNBRQRQNC!78!D."1S0!ZE1110
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M"/XU^#OC[X,M_$7@7Q5X=\9:#<G$6HZ)J,-_:N>X$D3,N1GD9R*ZJ@ HHHH
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MFB^()O#D\'B.UMK>Z>XBMK:X9U6">9#&4NHP"7!R&^4  D ^DJ*** "BBB@
MHHHH **_('_B-6_99_Z$']H#_P $>D?_ "SH_P"(U;]EG_H0?V@/_!'I'_RS
MH _7ZBOR!_XC5OV6?^A!_: _\$>D?_+.C_B-6_99_P"A!_: _P#!'I'_ ,LZ
M /U^HK\@?^(U;]EG_H0?V@/_  1Z1_\ +.C_ (C5OV6?^A!_: _\$>D?_+.@
M#]?J*_('_B-6_99_Z$']H#_P1Z1_\LZ/^(U;]EG_ *$']H#_ ,$>D?\ RSH
M_7ZBOR!_XC5OV6?^A!_: _\ !'I'_P LZ_03_@G-_P %"O!G_!3C]FFU^*G@
M'2_%&D^'KO4+G34M]?MH+>\$D#!7)6&:9-I)X._/J!0![U1110 4444 %%%8
M?Q#\:6OPV\ ZYXCOH[B:QT"PN-2N$@4-*\<,;2,$#$ L0IP"0,]QUH W**_(
M'_B-6_99_P"A!_: _P#!'I'_ ,LZ_33]D+]J#0/VTOV:O!OQ4\*V>L6'A_QO
MIZZE8V^JQ1Q7D,99E E6.21 V5/"NP]Z /2J*** "BBB@ HHHH **** "BBO
MC_\ ;*_X+M_LM?L*:A>:;XT^*6D7GB2Q8QRZ#X?5M8U*.09S'(D 9(&&#Q,\
M?ZC(!]@45^(GQ;_X/;OA3HD\B^!?@G\0/$R+G8^MZK::*)#SVB%T0"<>^#T[
M5Y-JW_!\5KTMZS6/[..D6]M@;8Y_&TDT@..<LMD@//\ LC\: /Z%**_!?X??
M\'P^AW=U#'XJ_9UU73X5"B6XTGQC'>LQP=Q6*2TB YQ@&0\$\\<_6G[-O_!V
M5^R%\?;JWL]:\0>*_A?J%QA!'XJT8K;E^X^T6K3QJO7YI"@QUP>* /TTHKE?
MA'\;?!OQ_P#"$/B#P+XL\-^,M"N/]7J&B:E#?VKGT\R)F7/MG(KJJ "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(_P#P
M75^"?BS]H_\ X)/?&3P3X&T*^\3>*M>TZTBT_3+-0T]VRW]M(P4$@<(C-UZ
MU]<44 ?QA_\ #@G]LC_HWKX@?^ \7_Q='_#@G]LC_HWKX@?^ \7_ ,77]GE%
M '\8?_#@G]LC_HWKX@?^ \7_ ,77._%__@C/^U%\!/AEK'C+QE\%?&GA_P ,
M>'[<W6HZC=P1K#:1 @%V(<G&2.W>O[7J^/\ _@OQ_P H;?VA/^Q5E_\ 1L=
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MFV ,5=IL!J_,6UMI+RYCAAC>221@B(B[F9CP !W)]*]P_P"">/\ P3X^(/\
MP4M_:6TGX9_#NQCDOKH?:=1U*YRMGHEDK*)+J=AR%7< %&6=F55!)%?U>?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\?_ /!?C_E#;^T)_P!BK+_Z-CK[ KX__P""_'_*&W]H3_L59?\ T;'0!_&'
M7]W?[)O_ ":S\,_^Q4TO_P!)(J_A$K^[O]DW_DUGX9_]BII?_I)%0!Z#1110
M 4444 %%%% !1110 5^<'_!U_P#\H2_B-_V%=$_].=O7Z/U^<'_!U_\ \H2_
MB-_V%=$_].=O0!_*%\*/^2H>&?\ L*VO_HY:_O<K^"/X4?\ )4/#/_85M?\
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M%5.,)8,;]V_X"MLS?AWZ5_:50 4444 %%%% !1110 4444 ?G+_P=#?MS_\
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MG_8J:I_Z22UZ#7GW[67_ ":S\3/^Q4U3_P!)): /X1*_L\_X(#_\H;?V>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^/_ /@OQ_RAM_:$_P"Q5E_]&QU]@5\?_P#!?C_E
M#;^T)_V*LO\ Z-CH _C#K^[O]DW_ )-9^&?_ &*FE_\ I)%7\(E?W=_LF_\
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M_P"-T ?U>_\ $4;^PI_T7+_RS/$'_P @U_(%7H'_  R=\4O^B:?$#_PG[O\
M^-UY_0!_7Y_P:Y?\H*/@7_W'_P#U(-3K] *_/_\ X-<O^4%'P+_[C_\ ZD&I
MU^@% !1110 4444 %%%% '\ =?T3?\$+O^#@S]ES]B'_ ()7?"WX7?$7QIK&
MD>,O#']K?;[2#P[?7<</VC5[VZBQ)'$R-F*:,\$X)P>0:_G9KM/"W[/GCWQS
MH<&J:)X'\8:QIEUN\F[LM&N;B";:Q5MKHA4X96!P>"".HH _JI_XBP/V)?\
MHHWB#_PDM3_^,T?\18'[$O\ T4;Q!_X26I__ !FOY8O^&3OBE_T33X@?^$_=
M_P#QNC_AD[XI?]$T^('_ (3]W_\ &Z /ZG?^(L#]B7_HHWB#_P )+4__ (S1
M_P 18'[$O_11O$'_ (26I_\ QFOY8O\ AD[XI?\ 1-/B!_X3]W_\;H_X9.^*
M7_1-/B!_X3]W_P#&Z /[*O\ @GY_P5>^"?\ P4^_X2[_ (4[XBU#Q!_P@_V/
M^U_M6D7-A]G^U^?Y&/.1=^[[--G;G&T9QD5])5^$/_!E'\)_%7PO_P"&F/\
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M?QA^.WC;]H;QA)X@\>^+_$WC779%V-J&NZI-J%SMR2%\R5F8*,G !P*^K?\
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M(_\ V"M$_P#39;U]/_\ !D1_R=-\</\ L5++_P!*S7S!_P '7_\ RFU^(_\
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MU/\ ^,T?\18'[$O_ $4;Q!_X26I__&:_EB_X9.^*7_1-/B!_X3]W_P#&Z/\
MAD[XI?\ 1-/B!_X3]W_\;H _J=_XBP/V)?\ HHWB#_PDM3_^,T?\18'[$O\
MT4;Q!_X26I__ !FOY8O^&3OBE_T33X@?^$_=_P#QNC_AD[XI?]$T^('_ (3]
MW_\ &Z /[E/@Y\5]%^//PB\*^.O#-S+>>&_&FCVFNZ5</"T+3VEU"D\+E& 9
M28W4[6 (S@C-=17@G_!+32;KP_\ \$ROV<[&^M;BROK+X8>&8+BWGC,<L$BZ
M5;*R.K8*LI!!!&01BO>Z "BBB@ HHHH **** /YH?^#V?_D_KX4_]D_7_P!.
M-Y7D'_!H=_RF1T3_ +%76/\ T4E>O_\ ![/_ ,G]?"G_ +)^O_IQO*\@_P"#
M0[_E,CHG_8JZQ_Z*2@#^KVBBB@ HHHH **** /X@_P#@K%_RE-_:6_[*KXH_
M].]U7[_?\&5/_*++Q]_V574?_31H]?@#_P %8O\ E*;^TM_V57Q1_P"G>ZK]
M_O\ @RI_Y19>/O\ LJNH_P#IHT>@#]?J*** "BBB@ HHHH **** "BBB@#^"
M/XK_ /)4/$W_ &%;K_T<U?U>_P#!J!_RA+^'/_85UO\ ].=Q7\H7Q7_Y*AXF
M_P"PK=?^CFK^KW_@U _Y0E_#G_L*ZW_Z<[B@#]'Z*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q_\
M\%^/^4-O[0G_ &*LO_HV.OL"OC__ (+\?\H;?VA/^Q5E_P#1L= '\8=?W=_L
MF_\ )K/PS_[%32__ $DBK^$2O[N_V3?^36?AG_V*FE_^DD5 'H-%%% !1110
M 4444 %%%% !7YP?\'7_ /RA+^(W_85T3_TYV]?H_7YP?\'7_P#RA+^(W_85
MT3_TYV] '\H7PH_Y*AX9_P"PK:_^CEK^]ROX(_A1_P E0\,_]A6U_P#1RU_>
MY0 4444 %%%% !7\ =?W^5_ '0!_7Y_P:Y?\H*/@7_W'_P#U(-3K] *_/_\
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M+_\ @ECXJT_2[Q;;Q9\6G_X0W2PKXDCAG1C?3 =<"U66/<,;7GB.<X!_DQ\
M>!=5^*/CO1?#.A6<NH:YXBOX-,T^UB&7N;B>18XHU'JSLH'UH ]@_8*_X*0?
M%;_@FIX^UKQ1\(]8TO0M<U[3QI5W=W6E6]^QMO,64QKYR,%!=$)Q@G8OI7U)
M_P 17_[;7_11_#__ (26F?\ QFOMRQ_X,;9GLX3<_M.0PW!13*D7P[,D:/CD
M*QU-2P!S@E1GT'2I/^(&/_JZ+_S&_P#]]* /A_\ XBO_ -MK_HH_A_\ \)+3
M/_C-'_$5_P#MM?\ 11_#_P#X26F?_&:^X/\ B!C_ .KHO_,;_P#WTH_X@8_^
MKHO_ #&__P!]* /Q\_;V_P""D/Q6_P""EGCW0_$WQ<UC2]<UWP_8'2[.[M=(
MMM/<6QD:41OY*+O"N[D;LXWMCJ:V?^"1O[;,_P#P3W_X*%_#3XH>=)'H^DZH
MMGKZ+SYVEW/[B[!7^(K$[2*/[\:'C&:_6:Z_X,:Y4MI6@_:=CDF5#Y:2?#LH
MK-C@%AJ9(!/< X]#TK\(/B-X!U;X4?$'7O"^O6;Z?KGAO4;C2M1M7^];7,$C
M12QGW5U8?A0!_>Q87T.IV4-U;317%O<(LL<L3ATE1AD,I'!!!!!'6K-?GG_P
M;(_MP-^VE_P2J\'V^I7ANO%7PM<^"]5+ONDD2V1#9RG/)#6KPJ6.=SQ2<Y!
M_0R@ HHHH **** "BBB@#^2'_@Z__P"4VOQ'_P"P5HG_ *;+>OF__@G7_P $
MN?BO_P %1?&GB+0/A19Z'>:AX5LH]0OUU+45LE6)Y/+7:6!W'=VKZ0_X.O\
M_E-K\1_^P5HG_ILMZ^G_ /@R(_Y.F^.'_8J67_I6: / /^(0[]LK_H"_#_\
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MBBB@ KX__P""_'_*&W]H3_L59?\ T;'7V!7Q_P#\%^/^4-O[0G_8JR_^C8Z
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M+_\ P^M_9'_Z.,^#_P#X4UM_\51_P^M_9'_Z.,^#_P#X4UM_\50!]045\O\
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M>K?\HLO /_95=._]-&L5^OU?D#_P>K?\HLO /_95=._]-&L4 ?@#_P $G?\
ME*;^S3_V57PO_P"G>UK^WROX<?\ @FMXWTGX:?\ !17X ^(O$&I6>CZ#X?\
MB/X=U+4K^[E$5O8VT.IV\DLTCGA41%9B3P ":_KN_P"'UO[(_P#T<9\'_P#P
MIK;_ .*H ^H**^7_ /A];^R/_P!'&?!__P *:V_^*H_X?6_LC_\ 1QGP?_\
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M>7/:W<"S0S+Z,C JP]B* /X$J_N[_9-_Y-9^&?\ V*FE_P#I)%2_\,G?"O\
MZ)G\/_\ PG;3_P"-UW%G9Q6%K'#!#'#!"@2.-%"K&H&  !P !Q@4 6**** "
MBBB@ HHHH **** "OS@_X.O_ /E"7\1O^PKHG_ISMZ_1^LGQ9X,T?Q]HDNF:
M[I6FZSILQ5I+2^MDN8'*G*DHX*G! (R."* /X.?A1_R5#PS_ -A6U_\ 1RU_
M>Y7G\/[*?PN@E62/X;^ HY(R&5E\/V@*D="#Y=>@4 %%%% !1110 5_ '7]_
ME>?_ /#)WPK_ .B9_#__ ,)VT_\ C= 'Q_\ \&N7_*"CX%_]Q_\ ]2#4Z_0"
MLOPMX3TOP/H$&EZ+IFGZ/I=KN\FSL+=+>WAW,6;:B *,LS$X'))/4UJ4 %%%
M% !1110 4444 ?P!T5_=Y_PR=\*_^B9_#_\ \)VT_P#C='_#)WPK_P"B9_#_
M /\ "=M/_C= '\(=%?W>?\,G?"O_ *)G\/\ _P )VT_^-T?\,G?"O_HF?P__
M /"=M/\ XW0!_"'17]WG_#)WPK_Z)G\/_P#PG;3_ .-T?\,G?"O_ *)G\/\
M_P )VT_^-T ?PAU_8Y_P;>?\H3/@'_V"KW_TYWE?4'_#)WPK_P"B9_#_ /\
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ML%W]U_PL7X4^)K/1[7+?V]IUO_:6CN@YW?:H-\:9'.V0H^ <J,'']L%% '\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>May 13, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wayne<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVALO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0705648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1500 Liberty Ridge Drive, Suite 321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">522-8707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="avtx-20260513.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="avtx-20260513.htm">avtx-20260513.htm</File>
    <File>avtx-20260513.xsd</File>
    <File>avtx-20260513_def.xml</File>
    <File>avtx-20260513_lab.xml</File>
    <File>avtx-20260513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "avtx-20260513.htm": {
   "nsprefix": "avtx",
   "nsuri": "http://www.avalotherapeutics.com/20260513",
   "dts": {
    "inline": {
     "local": [
      "avtx-20260513.htm"
     ]
    },
    "schema": {
     "local": [
      "avtx-20260513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "avtx-20260513_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avtx-20260513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avtx-20260513_pre.xml"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 21
   },
   "report": {
    "R1": {
     "role": "http://www.avalotherapeutics.com/role/CoverPageDocument",
     "longName": "0000001 - Document - Cover Page Document",
     "shortName": "Cover Page Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityAddressStateOrProvince",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avtx-20260513.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityAddressStateOrProvince",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avtx-20260513.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001534120-26-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001534120-26-000032-xbrl.zip
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M]%];)-FJNK9]#/):(H'V<5CJG$P)]CHG,R(PDD,U\B6F-Z>E;A@(D%UMM(@
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M 75!C='Y$-B+ Z[MSN.&LY/__Y-1 5R546 <I $/WW2)XS#TQQA8)&"AEJ;
MEE6M5L-QCK=9@OW)EJ(;)46VS;]3,H$3JW2B:&4?:!"#_7&L6BH;][97Y*Y*
MV6R@[OL!LFQ#AX[;G=/K$8\A6"(7.!!<GX.62B2*RH9S:+*Q333N2$2SE,9-
MN3 =#)YO1336MMN6@N& %U ]OP?9N&)$F@UY\E(=DI"VF5U.)C)6*"8CM6]%
M1H!4S5VA]5$[8CJ>9I7'1\4D)NG['<I,G_.8L"=(3OWU2HY--*?L%I.<M.^F
MY.P]JEMQE4F811@$:M'F.0MD*KU(PRZ@:'N4=7!90\O1'6?G+3';UIU:\\&D
MH>A4EJ'7Z\ZS3.6 Q6@\C%6:RCR2MRBCM+DG5^A,U,'7FT?R0D=RO,2=(M?'
MG!>HC'X7G&%8%2V&B]DX],N\2,6X$%^24Y&OE6T7Z5D%)4\D,^Q@%F^G%-[<
MV<Z\W8>G[H^_+GG<<$ [[@REKFIA6F.EWLN@HE'JR. $%F,H0O=S!?U3%HE,
M=(49^@/[\?9=\D=%_L?2%%J:U*@D-F6Y+DUY7&GTZ:6X_UH,4O[B7&#NX2^H
MBR,J("4XQ^PS$05VNPZKJ-@//!E2$S1>(%<5&"&\^PQ&E:A#(?>J?Y0CP [B
M<1D!7J-K%MZ*J8S,(UD1Q!QY9 (@U,FQI"QDU+*(]5Y-*#EI:Z.R#/<;QZHT
ME'6FZLQ9I,Z<A2P-[ZVQ9N7,E7M\-YM4AOIWXU:FU;=P_I&#C&OYI%TWUN53
MR?M:>@GP=\HNGVM5>]D*_9JL4#==H5UWVK)YDFG268JFFJU'4\V'2O"*F0=6
M@>]/'A#_"@A]KB[1C2+Z%#2%^)#6@:8$H4KR8DY4+V! 6JJ75\^I2OR2ZZF2
MZPJ6OY# U9<!Y)H&0!:T,')#.8P#_<.!*XL4V'7EV3;96=X2]S#S>%*D][9E
MF'89+S/,5<72L\P\7<YO)>_<]V[5/F^AKEX<CL)$5-J,^%AN"6]<);[#0H$W
M[H;@,3C@6&P?LLYWT]BRL@]?5=[YOK2QO# ]97?F]YIH8T;P9PU/ &H;^[=X
MP26O\F]5V_6_=ZM:6C<-:&78%6T>SX 5BWNWT$Q;OR?K?\5<T,EBKS<\S)HT
M3X+,D*4;UK::VH#PV!?J&,$E&)6TD@:F ;U?6HUN"%9,-FRZR!PKO4YK\6L
M>^#1A@DW+>#198!6+YE4T-D-]D,T@F '1R0&<\+5R0(=8AT>@YW$8#+ET0O0
M+(+!2.,@ *OJJIU58.6=N64I<Z69EO;S2ZQ.S:/$G$-X"%FJ;29@=70&)B):
M;J*N@X X91*S@/(I# 3$")AH+".=*1U3@5HMW7QUBY,&H\MOK<@(4D5L2Z%&
M9;H\\+'*BB/$IQ![*$<Z)A"!@G_VD#PW8@&:U">>^FT>JY4!MP>6CR@=6+J]
M9DY<*;4B+[:LR*7 LV15RW)0"FJU<PKQ:'FZ^A9\,^+Q^"\ *3VN'.=3/*9^
M DW!QY +)2A5@!J6TD57R;H[E T/$&8L/^$A^26C@70/?^M6;!IVKU)10>%F
MN;PB:RPD4A="R%S)ISPM0(3D(D0> #N])^*N(\%CD/,$BV]=2#>MK)59V99N
MF-NL[)TM50?FY.9%)DY*:OF.R<?>;639.]I&6T;"YMY#H?4[N #Q:1L33=TV
M\S<-MFTF;'MOZ0UGMQ%;<:KK->=O;4L<0.7E40U405QF_2]"'16H97T[1_F+
MD?^.<)?12/J) B?MZ\6NWZM"Q4HI;C,;^5O,W0G2<\OI\YZ+?]R(JE62H<E>
MA%/6HO(I?LAW3"9?PW<D>'G$3:^-M54<(GL!.C@WJR*),A^_)&XH^5 :F6NM
MEFE^D1$ZP1" !]<\C<GUJ0!-OUH-TRO(4U'8.3ZIXM= W>*5T(%>"1WR>W6O
M@I TYU74K-=;GN:VGM<UO4[W8QK."WN?/2<MW1"P0%<8TM>^7 50$GDUYAT6
M.+F?5R:S,?&\]*.ZJKP@N\J9D/KXKI=^Q"3GRMK!B6>12PP[9=;9=0OG:U>3
M<TNJ>[URE%][,K=7K5^P +U#[7T_&8C=?##(&_9_O3@;?1STGOTTZ:-6 # K
M%?OJRHL5GU>_GI5L"7Z)*4LK1,6VMBMY>XE>["^0BV.Y_Z>*ILE'G"28,4$<
M:(:&,/F8RYA,L3^1]3LYD5JZM(.L-,<!C%'3X5A,0P;$><]?QMM>!KJ;9L]U
MH)K>M.U=ZT#R2R^&]2SE&]O4&ZWG.>OZC$@U]-HC2.6[1^/EW./S!GDO@F3!
M,&M9?WKH=N_^RU/;/Y!5,/0O]&V(;T)Z=EW(/><(\B-];;3^S;T72AE>B@6_
M+-H[T'S@Q%1Y%76G#"*#,)*']X:Q[],;G%LE/BC]>NJ!T$-B_C?)^ -/[%/&
M4C)9.:!RJ3YVP?[N2=N<6#3]=-;7&O3=I]C6]A2[FOR7+^K_B>G\'U!+ P04
M    "  5.*U<L."?3'L"   X"   $0   &%V='@M,C R-C U,3,N>'-DW57)
M;MLP$+W[*UB=2RW>8ANQ S1!@ )N&Z0)FEM!D2.;B$2J)&4[?Q^2-NLH&ZJ>
MBNH@4#/OS<P;CLC3LUU5H@THS:681UF<1@@$E8R+U3RZO;G$D^ALT>N=?L#X
M[M/U$EU(VE0@##I70 PPM.5FC<P:T ^I[OF&H*N2F$*J"N.%IYW+^D'QU=J@
M?MH?!UCPJEF:3=ED,@2<G3# )W0TP?DH'^%\S,AT!.."]+./JQD=#PG-TQ0/
MV0FSKSY@ H,^'@P9&1< ,*',!]WIF:9KJ BRTH2>[?0\6AM3SY)DN]W&VT$L
MU2KIIVF6W'U9?O?0Z( MN;AOH7>Y*@-^D#AW3C0$.-F870M.-J24MAF*U- 8
M3G5,994XW>DH&T2(&*-XWABXM VZ@((TI9E'C?C5D)(7')CM?@FNORW $[<A
M:@7F*ZE UX1"E^R+'D*N.[RJI3)(O!JC+9@+;8B@5O"^I4M)B?&3\B;%?>'
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MGYH0%SXUQD'30+/:N?)WGBZ*'BFYY8@;#4@;HB0C@A&C([CQ2_8CNL0KJ7;
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M*%2Z*GQ(F#R?PQ$$(\FTGV^9$#27&C#T\)#V>PFR'Y<;)B"0C'" <!CR@(A
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MW97L#8$7DX:2OEU?SHY6%ZI#]2;DV=$_4$L#!!0    ( !4XK5QHMLU*:B4
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M6XODU62L0KA;L^_!/;:GJ1'R_+%EMPX37T7J2\T'H2#?#_#;=QG$T&2%V+X
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M6Q_*=P[UYE<^CU?K?!9:D&_!F"\0$"DJ>K5]M5J]:6ZEY;BM1WR%2*6;6]+
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M=SZ78H(%61JU'IINS(V3IJSYUIXPP'"S@(KL@6(13R_%VJALV0((EPA*<*R
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MPQ%UCPPW JER*]1;K?>9I!4[Z].*/^%Y%O"?<1:%O_Q_4$L! A0#%     @
M%3BM7$(957%Q#P  -FD  !$              ( !     &%V='@M,C R-C U
M,3,N:'1M4$L! A0#%     @ %3BM7+#@GTQ[ @  . @  !$
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M4$L! A0#%     @ %3BM7&BVS4IJ)0  4V(! !\              ( !SRH
M &5X+3DY,3%Q,C R-F5A<FYI;F=S<F5L96%S92YH=&U02P4&      8 !@"4
) 0  =E

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>avtx-20260513_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="avtx-20260513.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2026-05-13</startDate>
            <endDate>2026-05-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001534120</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">AVALO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37590</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">45-0705648</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1500 Liberty Ridge Drive, Suite 321</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Wayne</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">19087</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">522-8707</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">AVTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
